{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:50:41Z","timestamp":1786719041001,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"DOI":"10.7759\/cureus.114530","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:43:06Z","timestamp":1786714986000},"source":"Crossref","is-referenced-by-count":0,"title":["Radiomics for Differentiating Prostate-Specific Membrane Antigen (PSMA)-Positive and PSMA-Negative Lymph Nodes in Prostate Cancer: An Exploratory 68Ga-PSMA PET-CT Study"],"prefix":"10.7759","author":[{"given":"Alejandro","family":"Hern\u00e1ndez-Alejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier A","family":"Gonz\u00e1lez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haziel","family":"Maya-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Salinas-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ram\u00edrez-Rayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo  M","family":"Pacheco-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ram\u00edrez-Trejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Salinas-Chapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Elizondo Riojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/siuj6030044","article-title":"SIU-ICUD: epidemiology of prostate cancer","volume":"6","author":"Vieira Lima Aguiar Mel\u00e3o B","year":"2025","unstructured":"Vieira Lima Aguiar Mel\u00e3o B, Pekala KR, Matsoukas K, Bratt O, Carlsson SV. SIU-ICUD: epidemiology of prostate cancer. Soc Int Urol J. 2025, 6:44. 10.3390\/siuj6030044","journal-title":"Soc Int Urol J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.043","article-title":"Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy","volume":"55","author":"Briganti A","year":"2009","unstructured":"Briganti A, Karnes JR, Da Pozzo LF, et al.. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009, 55:261-70. 10.1016\/j.eururo.2008.09.043","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.05.005","article-title":"Can Ga-68 PSMA PET\/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?","volume":"6","author":"Esen T","year":"2020","unstructured":"Esen T, K\u0131l\u0131\u00e7 M, Seymen H, Acar \u00d6, Demirkol MO. Can Ga-68 PSMA PET\/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?. Eur Urol Focus. 2020, 6:218-20. 10.1016\/j.euf.2019.05.005","journal-title":"Eur Urol Focus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA pet on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han S","year":"2018","unstructured":"Han S, Woo S, Kim YJ, Suh CH. Impact of (68)Ga-PSMA pet on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018, 74:179-90. 10.1016\/j.eururo.2018.03.030","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.07.004","article-title":"Dual-energy CT texture analysis with machine learning for the evaluation and characterization of cervical lymphadenopathy","volume":"17","author":"Seidler M","year":"2019","unstructured":"Seidler M, Forghani B, Reinhold C, et al.. Dual-energy CT texture analysis with machine learning for the evaluation and characterization of cervical lymphadenopathy. Comput Struct Biotechnol J. 2019, 17:1009-15. 10.1016\/j.csbj.2019.07.004","journal-title":"Comput Struct Biotechnol J"},{"key":"ref7","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli RS","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54:1807-11.","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh A","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, et al.. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013, 40:486-95. 10.1007\/s00259-012-2298-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221109020","article-title":"Radiomics in prostate cancer: an up-to-date review","volume":"14","author":"Ferro M","year":"2022","unstructured":"Ferro M, de Cobelli O, Musi G, et al.. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol. 2022, 14:17562872221109020. 10.1177\/17562872221109020","journal-title":"Ther Adv Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173492","article-title":"Value of 68Ga-PSMA HBED-CC pet for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy","volume":"57","author":"Rauscher I","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, et al.. Value of 68Ga-PSMA HBED-CC pet for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016, 57:1713-9. 10.2967\/jnumed.116.173492","journal-title":"J Nucl Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3106-6","article-title":"PSMA PET\/CT with Glu-urea-Lys-(Ahx)-[\u2076\u2078Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer","volume":"42","author":"Giesel FL","year":"2015","unstructured":"Giesel FL, Fiedler H, Stefanova M, et al.. PSMA PET\/CT with Glu-urea-Lys-(Ahx)-[\u2076\u2078Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015, 42:1794-800. 10.1007\/s00259-015-3106-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7150\/thno.20855","article-title":"PSMA-PET for lymph node detection in recurrent prostate cancer: how do we use the magic bullet?","volume":"7","author":"Maurer T","year":"2017","unstructured":"Maurer T, Murphy DG, Hofman MS, Eiber M. PSMA-PET for lymph node detection in recurrent prostate cancer: how do we use the magic bullet?. Theranostics. 2017, 7:2046-7. 10.7150\/thno.20855","journal-title":"Theranostics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","author":"De Visschere PJ","year":"2019","unstructured":"De Visschere PJ, Standaert C, F\u00fctterer JJ, et al.. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. 2019, 2:47-76. 10.1016\/j.euo.2018.09.010","journal-title":"Eur Urol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies RJ","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016, 278:563-77. 10.1148\/radiol.2015151169","journal-title":"Radiology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2631","article-title":"The potential of radiomic-based phenotyping in precision medicine: a review","volume":"2","author":"Aerts HJ","year":"2016","unstructured":"Aerts HJ. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. 2016, 2:1636-42. 10.1001\/jamaoncol.2016.2631","journal-title":"JAMA Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts HJ","year":"2014","unstructured":"Aerts HJ, Velazquez ER, Leijenaar RT, et al.. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014, 5:4006. 10.1038\/ncomms5006","journal-title":"Nat Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin P","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R, et al.. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012, 48:441-6. 10.1016\/j.ejca.2011.11.036","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04971-z","article-title":"Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer","volume":"48","author":"Cysouw MC","year":"2021","unstructured":"Cysouw MC, Jansen BH, van de Brug T, et al.. Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021, 48:340-9. 10.1007\/s00259-020-04971-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771787","article-title":"Radiomics for identification and prediction in metastatic prostate cancer: a review of studies","volume":"11","author":"Kendrick J","year":"2021","unstructured":"Kendrick J, Francis R, Hassan GM, et al.. Radiomics for identification and prediction in metastatic prostate cancer: a review of studies. Front Oncol. 2021, 11:771787. 10.3389\/fonc.2021.771787","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov A","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, et al.. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012, 30:1323-41. 10.1016\/j.mri.2012.05.001","journal-title":"Magn Reson Imaging"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen JJ","year":"2017","unstructured":"van Griethuysen JJ, Fedorov A, Parmar C, et al.. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017, 77:e104-7. 10.1158\/0008-5472.CAN-17-0339","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg A","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, et al.. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020, 295:328-38. 10.1148\/radiol.2020191145","journal-title":"Radiology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera M","year":"2016","unstructured":"Perera M, Papa N, Christidis D, et al.. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016, 70:926-37. 10.1016\/j.eururo.2016.06.021","journal-title":"Eur Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden WJ","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950, 3:1-32. 10.1002\/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3","journal-title":"Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04864-1","article-title":"A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients","volume":"47","author":"Peeken JC","year":"2020","unstructured":"Peeken JC, Shouman MA, Kroenke M, et al.. A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. Eur J Nucl Med Mol Imaging. 2020, 47:2968-77. 10.1007\/s00259-020-04864-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.179648","article-title":"Correlation between SUVmax and CT radiomic analysis using lymph node density in PET\/CT-based lymph node staging","volume":"58","author":"Giesel FL","year":"2017","unstructured":"Giesel FL, Schneider F, Kratochwil C, et al.. Correlation between SUVmax and CT radiomic analysis using lymph node density in PET\/CT-based lymph node staging. J Nucl Med. 2017, 58:282-7. 10.2967\/jnumed.116.179648","journal-title":"J Nucl Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7150\/thno.32376","article-title":"Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference","volume":"9","author":"Zamboglou C","year":"2019","unstructured":"Zamboglou C, Carles M, Fechter T, et al.. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019, 9:2595-605. 10.7150\/thno.32376","journal-title":"Theranostics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498301-radiomics-for-differentiating-prostate-specific-membrane-antigen-psma-positive-and-psma-negative-lymph-nodes-in-prostate-cancer-an-exploratory-68ga-psma-pet-ct-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:43:07Z","timestamp":1786714987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498301-radiomics-for-differentiating-prostate-specific-membrane-antigen-psma-positive-and-psma-negative-lymph-nodes-in-prostate-cancer-an-exploratory-68ga-psma-pet-ct-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.114530","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}